Michael Chevrot
R&D, Head & Neck Group
Paris, France
Paris, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
HPV16 genomic status stratifies risk of disease recurrence in oropharyngeal squamous cell carcinoma.
HPV16 genomic status stratifies risk of disease recurrence in oropharyngeal squamous cell carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 18, 2026
Induction Nivolumab Before Chemoradiation in High-Risk Human Papillomavirus-Driven Oropharynx Cancers: IMMUNEBOOST-HPV, a Multicenter Randomized Phase II Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 22, 2026
Intensification or de-escalation? What is the standard treatment for human papillomavirus-related oropharyngeal cancers in 2025?
Journal: Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
Published: May 16, 2025
Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort.
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 04, 2023
Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program.
Journal: The oncologist
Published: February 11, 2023
Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes.
Journal: JAMA network open
Published: December 15, 2022
Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational Study.
Journal: Cancers
Published: December 10, 2022
Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation.
Journal: British journal of cancer
Published: October 13, 2022
Corrigendum to "De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): characteristics and prognosis" [Eur J Cancer 158 (2021) 181-188].
Journal: European journal of cancer (Oxford, England : 1990)
Published: March 22, 2022
Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort.
Journal: Breast (Edinburgh, Scotland)
Published: December 05, 2021
Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: October 12, 2021
De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): Characteristics and prognosis.
Journal: European journal of cancer (Oxford, England : 1990)
Published: July 15, 2021
Last Updated: 09/26/2026